Fundraising FoxRycarma
New York, US · 2 known investors
Find your way into Rycarma
Sign up to see every warm intro you have to Rycarma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rycarma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
RyCarma Therapeutics develops a novel drug class called Rycals to treat orphan skeletal muscle and cardiac diseases, building on foundational cardiovascular research and drug-delivery technologies.
Founders & leadership
AR
Andrew R. MarksFounding Scientist, MD
Investors · 2
Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M
How we know: Kurma Partners's portfolio page · the VCSheet dataset · Not right? Tell us
Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya
How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Rycarma do?
- RyCarma Therapeutics develops a novel drug class called Rycals to treat orphan skeletal muscle and cardiac diseases, building on foundational cardiovascular research and drug-delivery technologies.
- Who founded Rycarma?
- Rycarma was founded by Andrew R. Marks.
- Who are Rycarma's investors?
- Rycarma's investors include Kurma Partners, Pontifax Venture Capital.
- Where is Rycarma headquartered?
- Rycarma is headquartered in New York, US.